[ad_1] Galapagos has found a buyer for its once-promising JAK inhibitor Jyseleca (filgotinib), signing a letter of intent to transfer the drug and related operations to Alfasigma of Italy. Under the deal, Galapagos…
Tag: Alfasigma
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
[ad_1] Galapagos NV Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicines Aims to preserve the Jyseleca® (filgotinib) business and a…
Italy’s Alfasigma to buy drugmaker Intercept for nearly $800 mln
[ad_1] Sept 26 (Reuters) – Italy’s Alfasigma S.p.A said on Tuesday it had agreed to buy U.S. drugmaker Intercept Pharmaceuticals ICPT.O for $794 million to expand its presence in the…